2020
DOI: 10.1016/j.apnr.2020.151341
|View full text |Cite
|
Sign up to set email alerts
|

Postpartum glucose screening among women with gestational diabetes

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1

Citation Types

1
2
0

Year Published

2021
2021
2024
2024

Publication Types

Select...
6
1

Relationship

0
7

Authors

Journals

citations
Cited by 7 publications
(4 citation statements)
references
References 17 publications
1
2
0
Order By: Relevance
“…Our study’s strength is the large number of cases and the fact that they were treated following the same protocol by the same team throughout the study. We also acknowledge that this study has limitations, such as the relatively small percentage of patients that returned for postpartum testing (around 53%), but this rate is comparable to rates previously described [ 26 , 27 , 28 ]. Additionally, all our patients are treated for GDM after an early FPG equal to or higher than 92 mg/dL.…”
Section: Discussionsupporting
confidence: 66%
“…Our study’s strength is the large number of cases and the fact that they were treated following the same protocol by the same team throughout the study. We also acknowledge that this study has limitations, such as the relatively small percentage of patients that returned for postpartum testing (around 53%), but this rate is comparable to rates previously described [ 26 , 27 , 28 ]. Additionally, all our patients are treated for GDM after an early FPG equal to or higher than 92 mg/dL.…”
Section: Discussionsupporting
confidence: 66%
“…This index is similar to that found by Ortiz et al, 15 who found a rate of 19%. The prevalence of DM screening in patients with a history of GDM is quite variable in the literature, ranging from 13.8% to 41%, but what all the studies 13,14,[16][17][18][19] show, including the current study, is that even though screening is indicated for all postpartum women with a history of GDM, its performance is still low. Screening is important, as it enables the establishment of the risks of developing DM, so physicians can prescribe behavioral or even pharmacological changes to prevent or delay the its diagnosis in this population and avoid the impacts of this comorbidity in the long term.…”
Section: Discussionmentioning
confidence: 59%
“…O diagnóstico precoce do DMG, contribui com o aumento do monitoramento, podendo ocorrer uma maior intervenção durante a gravidez. Se inicia com a triagem durante o pré-natal, onde todas as gestantes devem ser rastreadas para o DMG entre as 24 e 28 semanas de gestação (Paul; Fitzpatrick, 2020).…”
Section: Resultsunclassified